From a recent study, it was concluded that the allopurinol use was not related to the reduced incidence of type 2 diabetes in gout patients. The incidence of diabetes is not found to be related to baseline serum urate or variation in serum urate level.

A study was conducted to find the association between allopurinol use and incidence of type-2 diabetes.

In this study, patients were divided into subgroups based on more than 30 continuous days of allopurinol administered, versus no allopurinol.  Six hundred and six, gout patients used allopurinol for more than 30 days continuously and 478 patients never used the allopurinol. 

After an average 7.9 ± 4.8 years of follow-up, no considerable variation in the diabetes incidence between the two groups was observed.

There is no correlation between allopurinol use and the reduced incidence of type 2 diabetes in gout patients.